LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 15

Search options

  1. Article ; Online: Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis.

    Shannon, Ashleigh / Selisko, Barbara / Le, Nhung-Thi-Tuyet / Huchting, Johanna / Touret, Franck / Piorkowski, Géraldine / Fattorini, Véronique / Ferron, François / Decroly, Etienne / Meier, Chris / Coutard, Bruno / Peersen, Olve / Canard, Bruno

    Nature communications

    2020  Volume 11, Issue 1, Page(s) 4682

    Abstract: The ongoing Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has emphasized the urgent need for antiviral therapeutics. The viral RNA-dependent-RNA-polymerase (RdRp) is a promising ... ...

    Abstract The ongoing Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has emphasized the urgent need for antiviral therapeutics. The viral RNA-dependent-RNA-polymerase (RdRp) is a promising target with polymerase inhibitors successfully used for the treatment of several viral diseases. We demonstrate here that Favipiravir predominantly exerts an antiviral effect through lethal mutagenesis. The SARS-CoV RdRp complex is at least 10-fold more active than any other viral RdRp known. It possesses both unusually high nucleotide incorporation rates and high-error rates allowing facile insertion of Favipiravir into viral RNA, provoking C-to-U and G-to-A transitions in the already low cytosine content SARS-CoV-2 genome. The coronavirus RdRp complex represents an Achilles heel for SARS-CoV, supporting nucleoside analogues as promising candidates for the treatment of COVID-19.
    MeSH term(s) Amides/pharmacokinetics ; Amides/pharmacology ; Animals ; Antiviral Agents/pharmacokinetics ; Antiviral Agents/pharmacology ; Betacoronavirus/drug effects ; Betacoronavirus/genetics ; COVID-19 ; Chlorocebus aethiops ; Coronavirus Infections/drug therapy ; Coronavirus Infections/virology ; Coronavirus RNA-Dependent RNA Polymerase ; Models, Molecular ; Mutagenesis/drug effects ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/virology ; Pyrazines/pharmacokinetics ; Pyrazines/pharmacology ; RNA, Viral/genetics ; RNA, Viral/metabolism ; RNA-Dependent RNA Polymerase/chemistry ; RNA-Dependent RNA Polymerase/metabolism ; SARS-CoV-2 ; Sequence Analysis ; Vero Cells ; Viral Nonstructural Proteins/chemistry ; Viral Nonstructural Proteins/metabolism ; Virus Replication/drug effects ; COVID-19 Drug Treatment
    Chemical Substances Amides ; Antiviral Agents ; Pyrazines ; RNA, Viral ; T 1105 ; Viral Nonstructural Proteins ; Coronavirus RNA-Dependent RNA Polymerase (EC 2.7.7.48) ; NSP12 protein, SARS-CoV-2 (EC 2.7.7.48) ; RNA-Dependent RNA Polymerase (EC 2.7.7.48) ; favipiravir (EW5GL2X7E0)
    Keywords covid19
    Language English
    Publishing date 2020-09-17
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-020-18463-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites.

    Shannon, Ashleigh / Le, Nhung Thi-Tuyet / Selisko, Barbara / Eydoux, Cecilia / Alvarez, Karine / Guillemot, Jean-Claude / Decroly, Etienne / Peersen, Olve / Ferron, Francois / Canard, Bruno

    Antiviral research

    2020  Volume 178, Page(s) 104793

    Abstract: The rapid global emergence of SARS-CoV-2 has been the cause of significant health concern, highlighting the immediate need for antivirals. Viral RNA-dependent RNA polymerases (RdRp) play essential roles in viral RNA synthesis, and thus remains the target ...

    Abstract The rapid global emergence of SARS-CoV-2 has been the cause of significant health concern, highlighting the immediate need for antivirals. Viral RNA-dependent RNA polymerases (RdRp) play essential roles in viral RNA synthesis, and thus remains the target of choice for the prophylactic or curative treatment of several viral diseases, due to high sequence and structural conservation. To date, the most promising broad-spectrum class of viral RdRp inhibitors are nucleoside analogues (NAs), with over 25 approved for the treatment of several medically important viral diseases. However, Coronaviruses stand out as a particularly challenging case for NA drug design due to the presence of an exonuclease (ExoN) domain capable of excising incorporated NAs and thus providing resistance to many of these available antivirals. Here we use the available structures of the SARS-CoV RdRp and ExoN proteins, as well as Lassa virus N exonuclease to derive models of catalytically competent SARS-CoV-2 enzymes. We then map a promising NA candidate, GS-441524 (the active metabolite of Remdesivir) to the nucleoside active site of both proteins, identifying the residues important for nucleotide recognition, discrimination, and excision. Interestingly, GS-441524 addresses both enzyme active sites in a manner consistent with significant incorporation, delayed chain termination, and altered excision due to the ribose 1'-CN group, which may account for the increased antiviral effect compared to other available analogues. Additionally, we propose structural and function implications of two previously identified RdRp resistance mutations in relation to resistance against Remdesivir. This study highlights the importance of considering the balance between incorporation and excision properties of NAs between the RdRp and ExoN.
    MeSH term(s) Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/chemistry ; Adenosine Monophosphate/pharmacology ; Alanine/analogs & derivatives ; Alanine/chemistry ; Alanine/pharmacology ; Antimetabolites/chemistry ; Antimetabolites/pharmacology ; Antiviral Agents/chemistry ; Antiviral Agents/pharmacology ; Betacoronavirus/chemistry ; Betacoronavirus/drug effects ; Betacoronavirus/genetics ; Betacoronavirus/metabolism ; COVID-19 ; Catalytic Domain ; Coronavirus Infections/drug therapy ; Coronavirus Infections/virology ; Coronavirus RNA-Dependent RNA Polymerase ; Drug Resistance, Viral ; Exoribonucleases/chemistry ; Exoribonucleases/genetics ; Exoribonucleases/metabolism ; Humans ; Models, Molecular ; Mutation ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/virology ; Protein Conformation ; RNA, Viral/chemistry ; RNA, Viral/genetics ; RNA-Dependent RNA Polymerase/chemistry ; RNA-Dependent RNA Polymerase/genetics ; RNA-Dependent RNA Polymerase/metabolism ; SARS-CoV-2 ; Structure-Activity Relationship ; Viral Nonstructural Proteins/chemistry ; Viral Nonstructural Proteins/genetics ; Viral Nonstructural Proteins/metabolism
    Chemical Substances Antimetabolites ; Antiviral Agents ; RNA, Viral ; Viral Nonstructural Proteins ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; nsp14 protein, SARS coronavirus (EC 2.1.1.56) ; Coronavirus RNA-Dependent RNA Polymerase (EC 2.7.7.48) ; NSP12 protein, SARS-CoV-2 (EC 2.7.7.48) ; RNA-Dependent RNA Polymerase (EC 2.7.7.48) ; Exoribonucleases (EC 3.1.-) ; Alanine (OF5P57N2ZX)
    Keywords covid19
    Language English
    Publishing date 2020-04-10
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2020.104793
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites

    Shannon, Ashleigh / Le, Nhung Thi-Tuyet / Selisko, Barbara / Eydoux, Cecilia / Alvarez, Karine / Guillemot, Jean-Claude / Decroly, Etienne / Peersen, Olve / Ferron, Francois / Canard, Bruno

    Antiviral Res

    Abstract: The rapid global emergence of SARS-CoV-2 has been the cause of significant health concern, highlighting the immediate need for antivirals. Viral RNA-dependent RNA polymerases (RdRp) play essential roles in viral RNA synthesis, and thus remains the target ...

    Abstract The rapid global emergence of SARS-CoV-2 has been the cause of significant health concern, highlighting the immediate need for antivirals. Viral RNA-dependent RNA polymerases (RdRp) play essential roles in viral RNA synthesis, and thus remains the target of choice for the prophylactic or curative treatment of several viral diseases, due to high sequence and structural conservation. To date, the most promising broad-spectrum class of viral RdRp inhibitors are nucleoside analogues (NAs), with over 25 approved for the treatment of several medically important viral diseases. However, Coronaviruses stand out as a particularly challenging case for NA drug design due to the presence of an exonuclease (ExoN) domain capable of excising incorporated NAs and thus providing resistance to many of these available antivirals. Here we use the available structures of the SARS-CoV RdRp and ExoN proteins, as well as Lassa virus N exonuclease to derive models of catalytically competent SARS-CoV-2 enzymes. We then map a promising NA candidate, GS-441524 (the active metabolite of Remdesivir) to the nucleoside active site of both proteins, identifying the residues important for nucleotide recognition, discrimination, and excision. Interestingly, GS-441524 addresses both enzyme active sites in a manner consistent with significant incorporation, delayed chain termination, and altered excision due to the ribose 1'-CN group, which may account for the increased antiviral effect compared to other available analogues. Additionally, we propose structural and function implications of two previously identified RdRp resistance mutations in relation to resistance against Remdesivir. This study highlights the importance of considering the balance between incorporation and excision properties of NAs between the RdRp and ExoN.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #32283108
    Database COVID19

    Kategorien

  4. Article ; Online: Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis

    Shannon, Ashleigh / Selisko, Barbara / Le, Nhung-Thi-Tuyet / Huchting, Johanna / Touret, Franck / Piorkowski, Géraldine / Fattorini, Véronique / Ferron, François / Decroly, Etienne / Meier, Chris / Coutard, Bruno / Peersen, Olve / Canard, Bruno

    ISSN: 2041-1723 ; EISSN: 2041-1723 ; Nature Communications ; https://www.hal.inserm.fr/inserm-02952494 ; Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.4682. ⟨10.1038/s41467-020-18463-z⟩

    2020  

    Abstract: International audience ... The ongoing Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has emphasized the urgent need for antiviral therapeutics. The viral RNA-dependent-RNA-polymerase ( ...

    Abstract International audience

    The ongoing Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has emphasized the urgent need for antiviral therapeutics. The viral RNA-dependent-RNA-polymerase (RdRp) is a promising target with polymerase inhibitors successfully used for the treatment of several viral diseases. We demonstrate here that Favipiravir predominantly exerts an antiviral effect through lethal mutagenesis. The SARS-CoV RdRp complex is at least 10-fold more active than any other viral RdRp known. It possesses both unusually high nucleotide incorporation rates and high-error rates allowing facile insertion of Favipiravir into viral RNA, provoking C-to-U and G-to-A transitions in the already low cytosine content SARS-CoV-2 genome. The coronavirus RdRp complex represents an Achilles heel for SARS-CoV, supporting nucleoside analogues as promising candidates for the treatment of COVID-19.
    Keywords [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ; [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry ; Molecular Biology/Molecular biology ; [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ; covid19
    Language English
    Publishing date 2020-09-17
    Publisher HAL CCSD
    Publishing country fr
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis

    Shannon, Ashleigh / Selisko, Barbara / Le, Nhung-Thi-Tuyet / Huchting, Johanna / Touret, Franck / Piorkowski, Géraldine / Fattorini, Véronique / Ferron, François / Decroly, Etienne / Meier, Chris / Coutard, Bruno / Peersen, Olve / Canard, Bruno

    ISSN: 2041-1723 ; EISSN: 2041-1723 ; Nature Communications ; https://www.hal.inserm.fr/inserm-02952494 ; Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.4682. ⟨10.1038/s41467-020-18463-z⟩

    2020  

    Abstract: International audience ... The ongoing Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has emphasized the urgent need for antiviral therapeutics. The viral RNA-dependent-RNA-polymerase ( ...

    Abstract International audience

    The ongoing Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has emphasized the urgent need for antiviral therapeutics. The viral RNA-dependent-RNA-polymerase (RdRp) is a promising target with polymerase inhibitors successfully used for the treatment of several viral diseases. We demonstrate here that Favipiravir predominantly exerts an antiviral effect through lethal mutagenesis. The SARS-CoV RdRp complex is at least 10-fold more active than any other viral RdRp known. It possesses both unusually high nucleotide incorporation rates and high-error rates allowing facile insertion of Favipiravir into viral RNA, provoking C-to-U and G-to-A transitions in the already low cytosine content SARS-CoV-2 genome. The coronavirus RdRp complex represents an Achilles heel for SARS-CoV, supporting nucleoside analogues as promising candidates for the treatment of COVID-19.
    Keywords [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ; [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry ; Molecular Biology/Molecular biology ; [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ; covid19
    Language English
    Publishing date 2020-09-17
    Publisher HAL CCSD
    Publishing country fr
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  6. Article ; Online: Remdesivir and SARS-CoV-2

    Shannon, Ashleigh / Le, Nhung Thi-Tuyet / Selisko, Barbara / Eydoux, Cecilia / Alvarez, Karine / Guillemot, Jean-Claude / Decroly, Etienne / Peersen, Olve / Ferron, Francois / Canard, Bruno

    ISSN: 0166-3542 ; Antiviral Research ; https://hal.archives-ouvertes.fr/hal-02890586 ; Antiviral Research, Elsevier Masson, 2020, 178, pp.104793. ⟨10.1016/j.antiviral.2020.104793⟩

    Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites

    2020  

    Abstract: International ... ...

    Abstract International audience
    Keywords [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ; covid19
    Language English
    Publisher HAL CCSD
    Publishing country fr
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article ; Online: Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis

    Shannon, Ashleigh / Selisko, Barbara / Le, Nhung-Thi-Tuyet / Huchting, Johanna / Touret, Franck / Piorkowski, Géraldine / Fattorini, Véronique / Ferron, François / Decroly, Etienne / Meier, Chris / Coutard, Bruno / Peersen, Olve / Canard, Bruno

    ISSN: 2041-1723 ; EISSN: 2041-1723 ; Nature Communications ; https://www.hal.inserm.fr/inserm-02952494 ; Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.4682. ⟨10.1038/s41467-020-18463-z⟩

    2020  

    Abstract: International audience ... The ongoing Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has emphasized the urgent need for antiviral therapeutics. The viral RNA-dependent-RNA-polymerase ( ...

    Abstract International audience

    The ongoing Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has emphasized the urgent need for antiviral therapeutics. The viral RNA-dependent-RNA-polymerase (RdRp) is a promising target with polymerase inhibitors successfully used for the treatment of several viral diseases. We demonstrate here that Favipiravir predominantly exerts an antiviral effect through lethal mutagenesis. The SARS-CoV RdRp complex is at least 10-fold more active than any other viral RdRp known. It possesses both unusually high nucleotide incorporation rates and high-error rates allowing facile insertion of Favipiravir into viral RNA, provoking C-to-U and G-to-A transitions in the already low cytosine content SARS-CoV-2 genome. The coronavirus RdRp complex represents an Achilles heel for SARS-CoV, supporting nucleoside analogues as promising candidates for the treatment of COVID-19.
    Keywords [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ; [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry ; Molecular Biology/Molecular biology ; [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ; covid19
    Language English
    Publishing date 2020-09-17
    Publisher HAL CCSD
    Publishing country fr
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  8. Article ; Online: Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis

    Shannon, Ashleigh / Selisko, Barbara / Le, Nhung-Thi-Tuyet / Huchting, Johanna / Touret, Franck / Piorkowski, Géraldine / Fattorini, Véronique / Ferron, François / Decroly, Etienne / Meier, Chris / Coutard, Bruno / Peersen, Olve / Canard, Bruno

    ISSN: 2041-1723 ; EISSN: 2041-1723 ; Nature Communications ; https://www.hal.inserm.fr/inserm-02952494 ; Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.4682. ⟨10.1038/s41467-020-18463-z⟩

    2020  

    Abstract: International audience ... The ongoing Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has emphasized the urgent need for antiviral therapeutics. The viral RNA-dependent-RNA-polymerase ( ...

    Abstract International audience

    The ongoing Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has emphasized the urgent need for antiviral therapeutics. The viral RNA-dependent-RNA-polymerase (RdRp) is a promising target with polymerase inhibitors successfully used for the treatment of several viral diseases. We demonstrate here that Favipiravir predominantly exerts an antiviral effect through lethal mutagenesis. The SARS-CoV RdRp complex is at least 10-fold more active than any other viral RdRp known. It possesses both unusually high nucleotide incorporation rates and high-error rates allowing facile insertion of Favipiravir into viral RNA, provoking C-to-U and G-to-A transitions in the already low cytosine content SARS-CoV-2 genome. The coronavirus RdRp complex represents an Achilles heel for SARS-CoV, supporting nucleoside analogues as promising candidates for the treatment of COVID-19.
    Keywords [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ; [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry ; Molecular Biology/Molecular biology ; [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ; covid19
    Language English
    Publishing date 2020-09-17
    Publisher HAL CCSD
    Publishing country fr
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: Remdesivir and SARS-CoV-2

    Shannon, Ashleigh / Le, Nhung Thi-Tuyet / Selisko, Barbara / Eydoux, Cecilia / Alvarez, Karine / Guillemot, Jean-Claude / Decroly, Etienne / Peersen, Olve / Ferron, Francois / Canard, Bruno

    ISSN: 0166-3542 ; Antiviral Research ; https://hal.archives-ouvertes.fr/hal-02890586 ; Antiviral Research, Elsevier Masson, 2020, 178, pp.104793. ⟨10.1016/j.antiviral.2020.104793⟩

    Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites

    2020  

    Abstract: International ... ...

    Abstract International audience
    Keywords [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ; covid19
    Language English
    Publisher HAL CCSD
    Publishing country fr
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  10. Article ; Online: Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis

    Shannon, Ashleigh / Selisko, Barbara / Le, Nhung-Thi-Tuyet / Huchting, Johanna / Touret, Franck / Piorkowski, Géraldine / Fattorini, Véronique / Ferron, François / Decroly, Etienne / Meier, Chris / Coutard, Bruno / Peersen, Olve / Canard, Bruno

    ISSN: 2041-1723 ; EISSN: 2041-1723 ; Nature Communications ; https://www.hal.inserm.fr/inserm-02952494 ; Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.4682. ⟨10.1038/s41467-020-18463-z⟩

    2020  

    Abstract: International audience ... The ongoing Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has emphasized the urgent need for antiviral therapeutics. The viral RNA-dependent-RNA-polymerase ( ...

    Abstract International audience

    The ongoing Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has emphasized the urgent need for antiviral therapeutics. The viral RNA-dependent-RNA-polymerase (RdRp) is a promising target with polymerase inhibitors successfully used for the treatment of several viral diseases. We demonstrate here that Favipiravir predominantly exerts an antiviral effect through lethal mutagenesis. The SARS-CoV RdRp complex is at least 10-fold more active than any other viral RdRp known. It possesses both unusually high nucleotide incorporation rates and high-error rates allowing facile insertion of Favipiravir into viral RNA, provoking C-to-U and G-to-A transitions in the already low cytosine content SARS-CoV-2 genome. The coronavirus RdRp complex represents an Achilles heel for SARS-CoV, supporting nucleoside analogues as promising candidates for the treatment of COVID-19.
    Keywords [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ; [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry ; Molecular Biology/Molecular biology ; [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ; covid19
    Language English
    Publishing date 2020-09-17
    Publisher HAL CCSD
    Publishing country fr
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top